Dan Lemaitre is Executive Chair of BlueWind Medical, an Israeli-based neuromodulation company.
Previously, Dan was a Medtech analyst on Wall Street for more than 20 years, initially at Cowen & Company and later, Merrill Lynch. He was voted to the Institutional Investor All-America Research Team for 19 consecutive years and was the top-ranked medical device analyst nine times.
After leaving Wall Street Mr. Lemaitre was Senior Vice President at Medtronic, where he ran Strategy and BD and served on both Op Com and Ex Com. Dan left Medtronic to become the CEO of CoreValve that launched the first commercial transcatheter aortic value replacement (TAVR) device in Europe in 2007. Corevalve was sold in 2009 for $800 million and today the TAVR market is ~$5B.
Mr. Lemaitre also currently serves as Chairman of Endologix (ELGX) and as a director of Globus Medical (GMED).